scholarly journals Case Report: Combination of Omalizumab and Dupilumab for Recalcitrant Bullous Pemphigoid

2021 ◽  
Vol 11 ◽  
Author(s):  
S. Morteza Seyed Jafari ◽  
Laurence Feldmeyer ◽  
Simon Bossart ◽  
Dagmar Simon ◽  
Christoph Schlapbach ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Case Report ◽  
Combination Therapy ◽  
Beneficial Effect ◽  
Bullous Pemphigoid ◽  
Skin Disease ◽  
Case Series ◽  
Complete Response ◽  
Preliminary Results ◽  
Alpha Antagonist

Bullous pemphigoid (BP) is a blistering autoimmune skin disease. Omalizumab, a monoclonal antibody directed to IgE, showed a beneficial effect in treatment of recalcitrant BP in case series. More recently, dupilumab, an interleukin (IL)-4-receptor alpha antagonist, also showed promising preliminary results. We describe a patient with refractory BP who showed a complete response to a combination therapy with omalizumab and dupilumab.

scholarly journals Successful Treatment of Pityriasis Rubra Pilaris with Brodalumab

2020 ◽  
Vol 4 (2) ◽  
pp. 139
Author(s):  
Umair Khan ◽  
Nahla Shihab ◽  
Robert G Phelps ◽  
Mark Lebwohl
Keyword(s):  
Combination Therapy ◽  
Successful Treatment ◽  
Skin Disease ◽  
Case Reports ◽  
Case Series ◽  
Inflammatory Skin Disease ◽  
Clinical Appearance ◽  
Pityriasis Rubra Pilaris ◽  
First Case ◽  
Inflammatory Skin

Pityriasis Rubra Pilaris (PRP) is a rare inflammatory skin disease with highly variable clinical appearance. Treatment of PRP remains a challenge and has been mostly guided by case reports and case series. We report the first case of pityrisis rubra pilaris that is successfully treated with combination therapy of brodalumab and methotrexate.

scholarly journals Case report of combination therapy with Azacytidine, Enasidenib and Venetoclax in primary refractory AML

2021 ◽  
Vol 10 (1) ◽  
Author(s):  
Sakshi Jasra ◽  
Mohammed Kazemi ◽  
Nishi Shah ◽  
Jiahao Chen ◽  
Karen Fehn ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Case Report ◽  
Combination Therapy ◽  
Elderly Patients ◽  
Myeloid Leukemia ◽  
Complete Response ◽  
First Case ◽  
Fda Approval ◽  
Acute Myeloid ◽  
Refractory Aml

AbstractOptimal treatment of acute myeloid leukemia (AML) arising in elderly patients remains a challenge. FDA approval of Ivosidenib and Enasidenib, small molecule inhibitors of isocitrate dehydrogenase enzymes (IDH1 and 2) have opened new avenues of treatment. We present a 60-year-old woman with refractory AML, achieving complete response to the combination therapy of hypomethylating agent, Azacytidine with the IDH2 inhibitor, Enasidenib, and BCL2 inhibitor, Venetoclax. To our knowledge, this is the first case report of a patient with IDH2 mutated refractory AML achieving complete response to combination therapy with azacytidine, enasidenib and venetoclax.

scholarly journals Bullous pemphigoid and radiotherapy: case report and literature review update

2021 ◽  
Author(s):  
Antonio Piras ◽  
Bruno Fionda ◽  
Antonella Sanfratello ◽  
Andrea D'Aviero ◽  
Giovanni Sortino ◽  
...  
Keyword(s):  
Case Report ◽  
Bullous Pemphigoid ◽  
Large Scale ◽  
Case Reports ◽  
Normal Skin ◽  
Disease Onset ◽  
Case Series ◽  
Characteristics Analysis ◽  
Meta Analyses

INTROUDCTION Bullous pemphigoid (BP) is a common autoimmune bullous disease generally occurring in elderly patients. Itchy and tense blisters on normal skin or erythematous and edematous lesions on the trunk and extremities usually characterize BP. Trigger factors are still unclear while several case reports suggest a potential role of radiotherapy (RT) as BP trigger for disease onset or recrudescence. A review was performed in order to provide an update of literature. A case report of a patient affected by BP undergoing two radiotherapy courses for a primary breast cancer was also reported. MATERIALS AND METHODS A comprehensive review of the published literature was conducted according to Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) guidelines. The review included studies describing BP and its relationships with RT treatments. RESULTS A total of 13 articles were reviewed. Studies characteristics analysis resulted in eleven case reports, one case series and one large-scale case–control study. CONCLUSIONS Literature update confirms the existence of a reasonable connection between RT and BP. Case report showed that a multidisciplinary management seems to assure the feasibility of RT in patients affected by BP, not depriving them of standard therapeutic opportunities.

scholarly journals Bullous Pemphigoid an Autoimmune Skin Disease: A Case Report

2020 ◽  
Vol 65 (1) ◽  
pp. 161-163
Author(s):  
Maheshwari V ◽  
Tasneem Abdul Gafoor ◽  
Ajeena Anto ◽  
Syam Prakash KR ◽  
Shahina KP ◽  
...  
Keyword(s):  
Case Report ◽  
Bullous Pemphigoid ◽  
Skin Disease

scholarly journals BULLOUS PEMPHIGOID A RARE AUTOIMMUNE DISEASE: A CASE REPORT

2019 ◽  
Vol 4 (2) ◽  
pp. 20-23
Author(s):  
S. M. Biradar ◽  
S. Dhanavidya ◽  
P. Kavya ◽  
T. Keerthi ◽  
N. Sunanda ◽  
...  
Keyword(s):  
Case Report ◽  
Bullous Pemphigoid ◽  
Male Patient ◽  
Skin Disease ◽  
The Elderly ◽  
Skin Lesions ◽  
Treatment Modalities ◽  
Susceptibility To Infection ◽  
Electrolyte Disturbances ◽  
Upper And Lower Extremities

Background. Bullous pemphigoid (BP) is a rare autoimmune blistering skin disease in the elderly and it is manifested by cutaneous blisters on the skin lesions. The objective was to emphasize the rare case of BP. Methods. A case report of BP in a 58-year-old male patient admitted to a dermatology ward is presented. Results. A 58-year-old male patient with complaints of fluid-filled skin lesions, was examined initially over the trunk, gradually progressed involving B/L upper and lower extremities. Even though the patient was treated with the recommended therapy of corticosteroid (Dexamethasone) along with adjuvant drugs, new skin lesions continued to develop, and the patient’s condition worsened. The Prednisolone was started in place of Dexamethasone on the fifth day of treatment at its higher dose (50mg/day), the Prednisolone proved its efficacy to combat the extensive condition of BP. Conclusions. Bullous pemphigoid is a distressing blistering skin disease. Untreated disease is often fatal because of the susceptibility to infection and fluid-electrolyte disturbances. The mortality of patients with bullous pemphigoid has been significantly reduced with the advent of new therapies and treatment modalities. The treatment with systemic and topical corticosteroids forms the mainstay of treatment along with other adjuvant drugs. In the present case study, the use of Prednisolone has proven its efficacy in the extensive disease state of BP and improved the patient’s quality of life.

scholarly journals Vancomycin plus nafcillin salvage for the treatment of persistent methicillin-resistant Staphylococcus aureus bacteremia following daptomycin failure: a case report and literature review

2018 ◽  
Vol 6 ◽  
pp. 204993611879740
Author(s):  
Paul O. Lewis ◽  
Regan E. Sevinsky ◽  
Paras D. Patel ◽  
Matthew R. Krolikowski ◽  
David B. Cluck
Keyword(s):  
Staphylococcus Aureus ◽  
Case Report ◽  
Combination Therapy ◽  
Salvage Therapy ◽  
Methicillin Resistant Staphylococcus Aureus ◽  
Case Reports ◽  
Case Series ◽  
Blood Cultures ◽  
Beta Lactam ◽  
Methicillin Resistant

Background: Evidence supporting beta-lactam plus vancomycin synergy for methicillin-resistant Staphylococcus aureus (MRSA) continues to grow. Current in vivo evidence demonstrates that combination therapy is associated with shorter time to blood sterilization than vancomycin monotherapy. However, this combination has not been reported as salvage therapy for persistent MRSA bacteremia. Case report: We report a case of an 81-year-old male who was successfully treated with vancomycin plus nafcillin after failing vancomycin monotherapy, daptomycin monotherapy, and daptomycin plus gentamicin combination therapy. The patient originally presented with sepsis from a suspected urinary tract infection. Blood cultures drawn on days 1, 3, 5, 15, 19, 23, and 28 remained positive for MRSA despite multiple antimicrobial therapy changes. On day 29, therapy was changed to vancomycin plus nafcillin. Blood cultures drawn on day 32 remained negative. After 11 days, nafcillin was changed to piperacillin–tazobactam due to an infected decubitus ulcer. The combination was continued for 42 days after achieving blood sterility, 71 days after the patient originally presented. Evidence regarding salvage therapy for persistent bacteremia is sparse and is limited to case reports and case series. Conclusion: This case report supports that vancomycin plus an anti-staphylococcal beta-lactam combination should be further studied as salvage therapy for persistent MRSA bacteremia.

Bullous Pemphigoid in an Infant: A Case Report

2018 ◽  
Vol 33 (4) ◽  
pp. 448-450 ◽  
Author(s):  
Oscar Thabouillot ◽  
Julien Le Coz ◽  
Nicolas-Charles Roche
Keyword(s):  
Emergency Department ◽  
Differential Diagnosis ◽  
Case Report ◽  
General Practitioner ◽  
Prior Knowledge ◽  
Bullous Pemphigoid ◽  
Skin Disease ◽  
Topical Steroids ◽  
Johnson Syndrome ◽  
Steven Johnson Syndrome

AbstractA seven-month-old girl was referred to the emergency department (ED) after a general practitioner suspected Steven-Johnson syndrome. Actually, the diagnosis of bullous pemphigoid (BP) was made based on biopsies; BP is a rare, autoimmune skin disease involving the presence of blisters known as bullae. The child was efficiently treated with topical steroids. This case shows the importance of the ED physician’s prior knowledge of BP so that a differential diagnosis with other autoimmune diseases (dermatosis, pemphigus) can be made.Thabouillot O, Le Coz J, Roche NC. Bullous pemphigoid in an infant: a case report. Prehosp Disaster Med. 2018;33(4):448–450.

Sign in / Sign up

Export Citation Format

Share Document